(Q45752433)

15 December 2017

review article

1 reference

title

Combination chemotherapy for human immunodeficiency virus-1. (English)

1 reference

15 December 2017

1 reference

D J Manion

1

1 reference

15 December 2017

M S Hirsch

series ordinal

2

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 May 1997

1 reference

15 December 2017

American Journal of Medicine

published in

1 reference

15 December 2017

volume

102

1 reference

15 December 2017

issue

5B

1 reference

15 December 2017

page(s)

76-80; discussion 81-2

1 reference

15 December 2017

HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Clinical Evaluation of Branched DNA Signal Amplification for Quantifying HIV Type 1 in Human Plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Viral counts count in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinica

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2897%2900068-5

10.1016/S0002-9343(97)00068-5

7 January 2021

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017